CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 267 enrolled
Drug / intervention
MEDI4736 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02319044
NCT02319044Phase 2Completed
CompareCT.gov

A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

AstraZeneca·interventional·Posted Dec 18, 2014·Updated Sep 29, 2020

In Brief

A Phase 2 clinical trial evaluating MEDI4736, Tremelimumab, and 1 other intervention for Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck. Completed, enrolled 267 participants across 125 sites in 15 countries.

Detailed Summary

The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
CountriesAustralia, Belgium, Canada, Czechia, France, Georgia, Germany, Hungary, Israel, Malaysia, South Korea, Spain, Taiwan, United Kingdom, United States
CollaboratorsPRA Health Sciences

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 18, 2014
Enrollment StartApr 15, 2015
Primary CompletionSep 26, 2016
Study CompletionJul 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.5 years ago

Interventions

MEDI4736drug

MEDI4736 monotherapy

Tremelimumabdrug

Tremelimumab monotherapy

MEDI4736 + Tremelimumabdrug

MEDI4736 + Tremelimumab combination therapy